Search results for "pic"

showing 10 items of 8215 documents

SARS-CoV-2 and the Risk Assessment Document in Italian Work: Specific or Generic Risk Even If Aggravated?

2021

In December 2019, several cases of atypical pneumonia were detected in Wuhan city, Hubei province, inland China. The initial outbreak was of considerable size first in China subsequently spread to the rest of the world. Immediately after the epidemic (which according to the World Health Organization had risen to pandemic status), the problem of whether or not to update the occupational risk assessment arose, also considering how the biological risk from SARS CoV-2 should be understood: specific or generic. To this end, we conducted a literature review to identify national health legislation and policies, examining how Italy has addressed the COVID-19 emergency in occupational health plannin…

medicine.medical_specialtyChinaoccupational medicineHealth Toxicology and Mutagenesislcsh:MedicineLegislationReviewSettore MED/42 - Igiene Generale E ApplicataRisk AssessmentOccupational safety and healthOccupational medicine03 medical and health sciences0302 clinical medicineCOVID-19 Decree 81/2008 Law Occupational medicine Prevention and protection measures Risk assessment document Work China Humans Italy Risk Assessment COVID-19 SARS-CoV-2workEnvironmental healthPandemicmedicineHumansprevention and protection measures030212 general & internal medicinelawChina0303 health sciences030306 microbiologySARS-CoV-2lcsh:RPublic Health Environmental and Occupational HealthCOVID-19medicine.diseasedecree 81/2008Work (electrical)Italyrisk assessment documentAtypical pneumoniaBusinessRisk assessment
researchProduct

Cholangitis prevention in endoscopic Klatskin tumor palliation: air cholangiography technique.

2009

INTRODUCTION: Endoscopic biliary drainage is the treatment of choice for inoperable hilar cholangiocarcinoma (so-called Klatskin tumor). Cholangitis is the main complication post-endoscopic retrograde cholangiopancreatography (ERCP) in Klatskin patients, specially when medium contrast is injected into biliary tree that could not be subsequently drained. Bacterial cholangitis is the principal cause of mortality in these patients. The aim of this study is to analyze cholangitis rate resulting from the use of air versus iodine contrast to obtain cholangiography during ERCP. METHODS: In 9 years, 188 inoperable Klatskin patients were recruited and divided into two groups: iodine (A) or air (B) c…

medicine.medical_specialtyCholangitisPopulationContrast MediaHepatic Duct CommonCohort StudiesCholangiographymedicineHumanseducationRetrospective StudiesCholangiopancreatography Endoscopic Retrogradeeducation.field_of_studymedicine.diagnostic_testERCP Klatskinbusiness.industryPalliative CareCholangitiair cholangiographyVascular surgerymedicine.diseasedigestive system diseasesIopamidolCardiac surgeryPneumoradiographySettore MED/18 - Chirurgia GeneraleKlatskin tumorBile Duct NeoplasmsCardiothoracic surgeryStentsSurgeryRadiologyComplicationbusinessKlatskin TumorAbdominal surgery
researchProduct

Is it really important for sick people to perform exercise?

2006

medicine.medical_specialtyChronic diseasebusiness.industryMEDLINEPhysical therapyReview Literature as TopicMedicinePhysical Therapy Sports Therapy and RehabilitationOrthopedics and Sports MedicineExercise therapyEvidence-based medicinebusinessQuality-adjusted life yearScandinavian Journal of Medicine and Science in Sports
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Clinical Trial Results of Peginterferons in Combination with Ribavirin

2003

Of the large number of patients chronically infected with hepatitis C virus (HCV), only about one third have progressive liver disease, and will eventually develop cirrhosis and hepatocellular carcinoma. These are the patients for whom effective antiviral treatment is most needed. Therapy is currently recommended for patients with chronic hepatitis C who have abnormal alanine aminotransferase (ALT) levels, detectable hepatitis C virus ribonucleic acid (HCV RNA) in the blood, and significant necroinflammatory changes and/or fibrosis on liver biopsy. The current gold standard in terms of treatment efficacy is the combination of peginterferon (PEG-IFN) and ribavirin. The overall sustained viro…

medicine.medical_specialtyCirrhosisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolsantiviral agentchemistry.chemical_compoundPharmacotherapyInternal medicineRibavirinmedicineHumansClinical Trials as TopicDrug CarriersHepatologymedicine.diagnostic_testbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesTreatment OutcomechemistryLiver biopsyHepatocellular carcinomaImmunologyclinical trials hepatitis CDrug Therapy CombinationbusinessViral loadSeminars in Liver Disease
researchProduct

Psychiatric and behavioural symptoms and the use of psychotropic medication in Special Care Units and Regular Units in Norwegian nursing homes

2008

Background:  In a number of countries Special Care Units (SCUs) have been established to meet the particular needs of patients with dementia. The criteria for SCUs are poorly defined and often not met. Aim:  To assess the frequency distributions of dementia, psychiatric and behavioural symptoms and the use of psychotropic medication in SCUs and Regular Units (RUs) across different regions. Methods and material:  By means of a structured interview, comprising the Neuropsychiatric Inventory, the Clinical Dementia Rating Scale and Lawton’s Physical Self-maintenance scale, a representative sample of 1163 nonselected nursing home patients was assessed. In addition, information was collected from…

medicine.medical_specialtyClinical Dementia RatingMEDLINEBehavioral SymptomsNorwegianAlzheimer DiseaseHomes for the AgedHumansMedicineDementiaEthics MedicalPsychiatryAgedPsychotropic DrugsNorwaybusiness.industryPublic Health Environmental and Occupational HealthHealth services researchmedicine.diseaselanguage.human_languageNursing HomesPsychotic DisordersStructured interviewlanguageAlzheimer's diseasebusinessNursing homesScandinavian Journal of Caring Sciences
researchProduct

Clinical and research aspects of ambulatory blood pressure monitoring in children.

2004

medicine.medical_specialtyClinical Trials as TopicAmbulatory blood pressurebusiness.industryHemodynamicsBlood Pressure Monitoring AmbulatorySurgeryMean blood pressureBlood pressureTreatment OutcomeReference ValuesInternal medicinePediatrics Perinatology and Child HealthHypertensionmedicineCardiologyHumansbusinessChildBody mass indexThe Journal of pediatrics
researchProduct

The treatment of portal hypertension: a meta-analytic review.

1995

medicine.medical_specialtyClinical Trials as TopicHepatologybusiness.industryVascular diseaseMEDLINEHemorrhageVariceal hemorrhagemedicine.diseaseGastroesophageal variceslaw.inventionSurgeryVaricose VeinsText miningRandomized controlled triallawRecurrenceRisk FactorsMeta-analysisHypertension PortalmedicinePortal hypertensionHumansIntensive care medicinebusinessHepatology (Baltimore, Md.)
researchProduct

The necessity of placebo application in psychotropic drug trials.

1990

medicine.medical_specialtyClinical Trials as TopicPsychotropic DrugsPsychotherapistMEDLINEGeneral MedicinePlaceboClinical trialPlacebosPsychiatry and Mental healthPsychotropic drugmedicineHumansPharmacology (medical)PsychopharmacologyPsychiatryPsychologyDepression (differential diagnoses)Randomized Controlled Trials as TopicPharmacopsychiatry
researchProduct

Considerations to the policy of future clinical therapeutic trials in DMD.

2002

In spite of rapidly increasing insight into the molecular basis of neuromuscular diseases, treatment still relies on convention and clinical studies. Experience with a multicentre double blind treatment study in Duchenne muscular dystrophy and with consecutive steroid treatment documentation for up to 8 years enables us to identify a series of crucial points on which to focus while planning such clinical trials. The most important seem to be: a carefully structured, detailed study, clear-cut aims and objectives, expertise of investigators, sufficient training of examiners, and careful monitoring. If patients with neuromuscular diseases are treated outside structured studies, their course sh…

medicine.medical_specialtyClinical Trials as Topicbusiness.industryDuchenne muscular dystrophymedicine.diseaseTherapeutic trialClinical trialDouble blindMuscular Dystrophy DuchenneSteroid therapyDocumentationNeurologyTreatment studyPediatrics Perinatology and Child HealthPhysical therapyMedicineHumansMulticenter Studies as TopicNeurology (clinical)businessGenetics (clinical)Follow-Up StudiesNeuromuscular disorders : NMD
researchProduct